| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | TAL; TALH; TAL-H; TALDOR |
| WB Predicted band size | 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human TALDO1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是基于TALDO1相关研究的模拟参考文献示例(仅供参考，具体文献需通过学术数据库核实)：
---
1. **文献名称**: *"TALDO1 Expression in Hepatocellular Carcinoma: A Prognostic Biomarker Study"*
**作者**: Li Y, et al.
**摘要**: 本研究通过免疫组化(IHC)和Western blot分析，发现TALDO1蛋白在肝癌组织中显著高表达，且与患者预后不良相关。使用兔源多克隆TALDO1抗体(ABC公司)验证了其作为潜在生物标志物的价值。
2. **文献名称**: *"Role of TALDO1 in Cellular Redox Homeostasis via the Pentose Phosphate Pathway"*
**作者**: Smith J, Patel R.
**摘要**: 通过CRISPR敲除细胞模型和TALDO1特异性抗体(货号#AB123. Sigma)，证实TALDO1缺失导致NADPH/GSH水平下降，并增加氧化应激敏感性，表明其在维持细胞氧化还原平衡中的关键作用。
3. **文献名称**: *"Validation of a Novel Monoclonal Antibody for TALDO1 in Metabolic Disorders"*
**作者**: Garcia S, et al.
**摘要**: 报道了一种高特异性小鼠抗人TALDO1单克隆抗体的开发与验证(ELISA/WB/IHC)，并应用于代谢疾病模型，发现TALDO1在肝脏和肾脏中的异常表达与果糖代谢紊乱相关。
4. **文献名称**: *"TALDO1 Knockdown and Antibody-Based Detection in Diabetic Nephropathy"*
**作者**: Kim H, et al.
**摘要**: 利用siRNA沉默TALDO1基因及兔多克隆抗体(Proteintech, 1:1000稀释)进行蛋白检测，证明TALDO1下调加剧糖尿病肾病模型中的炎症反应和纤维化进程。
---
**建议**：实际文献需通过PubMed、Google Scholar等平台搜索关键词“TALDO1 antibody” “TALDO1 immunohistochemistry”等获取，并关注近5年研究以获最新进展。
The TALDO1 antibody targets the transaldolase 1 protein, encoded by the TALDO1 gene in humans. Transaldolase 1 is a key enzyme in the pentose phosphate pathway (PPP), a metabolic route that generates NADPH and ribose-5-phosphate, essential for nucleotide synthesis and cellular redox balance. TALDO1 catalyzes the reversible transfer of a three-carbon ketol unit between sugar phosphates, linking the PPP to glycolysis. Dysregulation of TALDO1 has been implicated in metabolic disorders, cancer progression, and mitochondrial dysfunction.
TALDO1 antibodies are widely used in research to study the protein's expression, localization, and function in various tissues and disease models. They are critical tools for detecting TALDO1 via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Studies using these antibodies have revealed associations between TALDO1 deficiency and rare genetic disorders, such as transaldolase deficiency, characterized by liver dysfunction, developmental delays, and abnormal coagulation. In cancer biology, TALDO1 overexpression has been linked to tumor proliferation and metastasis, highlighting its potential as a therapeutic target.
Commercial TALDO1 antibodies are typically validated for specificity and sensitivity, often using knockout controls. Researchers rely on these reagents to explore metabolic adaptations in diseases, offering insights into PPP-driven mechanisms underlying cellular stress responses and pathological conditions.
×
